SARS-COV-2 大流行对 EUSOMA 认证乳腺中心乳腺癌诊疗质量的影响
研究比较了 EUSOMA 认证乳腺中心在 2020 年 3 月 1 日至 6 月 30 日(COVID-19 第一波高峰)与 2019 年同期基于个体记录的 EUSOMA 质量指标,45 家中心提供数据,31 家(67%)回复问卷;新发病例总数下降 19%,就诊时肿瘤分期(p=0.003)和淋巴结分期(p=0.011)略高且具统计学显著性,多因素分析显示质量指标差异大多无统计学显著性,结论认为乳腺癌诊疗质量维持良好。
要点
- 新发乳腺癌病例总数下降 19%,就诊时肿瘤分期(p=0.003)和淋巴结分期(p=0.011)略高。
- 94% 的中心可在无 COVID 区域手术,96% 的中心术前进行 COVID 检测,55% 的中心手术量减少。
- 新辅助内分泌、化疗和靶向治疗适应证修改分别见于 23%、23% 和 10% 的中心。
核心结论
- EUSOMA 乳腺中心在 COVID-19 第一波疫情期间乳腺癌诊疗质量维持良好,但就诊时肿瘤和淋巴结分期略高且具统计学显著性。
研究设计与样本
- 基于假名化个体记录比较 EUSOMA 质量指标,时段为 2020 年 3 月 1 日至 6 月 30 日与 2019 年 3 月 1 日至 6 月 30 日,45 家中心提供数据。
- 向参与中心发放问卷以调查 COVID-19 大流行对组织和乳腺癌诊疗质量的影响,31 家(67%)回复。
主要发现
- 新发病例总数下降 19%,就诊时肿瘤分期略高(p=0.003),淋巴结分期略高(p=0.011)。
- 对 12,736 例患者的质量指标进行多因素分析,差异大多无统计学显著性。
- 94% 的中心可在无 COVID 区域进行手术,96% 的中心术前进行 COVID 检测,55% 的中心手术量减少。
- 新辅助内分泌治疗、化疗和靶向治疗的适应证修改分别见于 23%、23% 和 10% 的中心。
- 辅助内分泌、化疗、靶向、免疫和放疗的适应证改变分别见于 3%、19%、3%、6% 和 10% 的中心。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We analysed the impact of the SARS-CoV-2 pandemic (COVID-19) on the quality of breast cancer care in certified EUSOMA (European Society of Breast Cancer Specialists) breast centres. MATERIALS AND METHODS: The results of the EUSOMA quality indicators were compared, based on pseudonymised individual records, for the periods 1 March 2020 till 30 June 2020 (first COVID-19 peak in most countries in Europe) and 1 March 2019 till 30 June 2019. In addition, a questionnaire was sent to the participating Centres for investigating the impact of the COVID-19 pandemic on the organisation and the quality of breast cancer care. RESULTS: Forty-five centres provided data and 31 (67%) responded to the questionnaire. The total number of new cases dropped by 19% and there was a small significant higher tumour (p = 0.003) and lymph node (p = 0.011) stage at presentation. Comparing quality indicators (12,736 patients) by multivariable analysis showed mostly non-significant differences. Surgery could be performed in a COVID-free zone in 94% of the centres, COVID testing was performed before surgery in 96% of the centres, and surgical case load was reduced in 55% of the centres. Modifications of the indications for neoadjuvant endocrine therapy, chemotherapy, and targeted therapy were necessary in 23%, 23%, and 10% of the centres; changes in indications for adjuvant endocrine, chemo-, targeted, immune, and radiotherapy in 3%, 19%, 3%, 6%, and 10%, respectively. CONCLUSION: Quality of breast cancer care was well maintained in EUSOMA breast centres during the first wave of the COVID-19 pandemic. A small but significantly higher tumour and lymph node stage at presentation was observed.
引用
- van Dam P, Tomatis M, Ponti A, et al. The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres. Eur J Cancer. 2022. PMID: 36332437. doi:10.1016/j.ejca.2022.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。